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Objective: Long-acting injectable risperi-
done represents the first clinically avail-
able depot atypical antipsychotic. The
present study used positron emission to-
mography (PET) to evaluate its dopamine
D2 binding profile at doses of 25, 50, or 75
mg administered every 2 weeks.
Method: After achieving stabilization
with one of the doses, nine patients with
a diagnosis of schizophrenia or schizoaf-
fective disorder underwent [11C]raclo-
pride PET to measure D2 occupancy. Par-
ticipants were scanned twice during the
2-week injection interval: within 3 days
after injection (postinjection) and within 5
days before the next injection (preinjec-
tion). At the same time, plasma was col-
lected for measurements of risperidone
plus 9-hydroxyrisperidone.
Results: Mean post- and preinjection D2
occupancy levels for the 25-, 50-, and 75-
mg doses were 71.0% and 54.0%, 74.4%
and 65.4%, and 81.5% and 75.0%, respec-
tively. There was a significant correlation
between dose and plasma concentra-
tions of risperidone plus 9-hydroxyris-
peridone, and the estimated plasma con-
centrat ion associated with 50% D2
occupancy (ED50) was 11.06 ng/ml. Pro-
lactin levels were not correlated with
drug levels or D2 occupancy.
Conclusions: All three doses of inject-
able risperidone showed peak D2 occu-
pancy levels above the 65% threshold as-
sociated with optimal clinical response;
the 75-mg dose approximated the 80%
threshold linked to increased risk of ex-
trapyramidal symptoms. Doses of 25 or
50 mg should provide therapeutic effi-
cacy while minimizing the risk of extrapy-
ramidal symptoms.
(Am J Psychiatry 2006; 163:396–401)
Long-acting depot antipsychotics were introduced for
clinical use in the 1960s, and among their advantages
compared with oral agents was the greater assurance of
medication delivery, reflected in decreased relapse rates
(1, 2). While the use of depot antipsychotics varied be-
tween countries and settings (3, 4), they have proven to be
a useful and important option in our treatment armamen-
tarium (2, 5).
A shift in practice patterns took place in the 1990s with
the influx of a number of novel antipsychotics, and the
clinical advantages of these newer “atypical” agents rap-
idly positioned them as the treatment of choice for psy-
chotic conditions such as schizophrenia (6–8). Despite
their identified benefits, however, adherence has re-
mained an issue (9, 10).
It is only recently, with the introduction of long-acting,
injectable risperidone, that clinicians have had access to a
depot atypical antipsychotic. This formulation represents
an aqueous suspension that contains the drug in a matrix
of glycolic acid-lactate polymer, and gradual hydrolysis of
the copolymer at the injection site allows slow but steady
release of risperidone over several weeks (11, 12). Various
trials have indicated that it is an effective and well-toler-
ated treatment when administered every 2 weeks (13–16).
Positron emission tomography (PET) studies of antipsy-
chotics, focusing in particular on dopamine D2 receptor
occupancy, have proven valuable in understanding the re-
lationship between dose, clinical response, and D2-related
adverse events (e.g., extrapyramidal symptoms). Most of
this work has involved oral antipsychotics (17–20), al-
though at least one report with haloperidol decanoate has
suggested that peak occupancies for the depot are in line
with what is observed in oral formulations (21).
Building upon the existing clinical evidence for long-act-
ing risperidone, we set out to evaluate the D2 receptor oc-
cupancy of various doses using PET. The study was not de-
signed as a clinical efficacy trial but rather was intended to
provide occupancy data that, in the context of our current
understanding, could provide additional in vivo evidence
regarding appropriate dosing with this new formulation.
Method
Subjects were recruited from a multicenter study investigating
the use of long-acting risperidone administered every 2 weeks at
three different doses (25, 50, or 75 mg) in individuals with schizo-
phrenia or schizoaffective disorder (13). The PET investigation
was approved by the Human Subjects Review Committee of the
University of Toronto, and subjects provided written informed
consent after receiving detailed information about the protocol.
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Details of the multicenter trial have been published elsewhere,
including design and clinical results (13). Briefly summarizing,
patients were candidates for a switch to long-acting risperidone if
they met DSM-IV criteria for schizophrenia or schizoaffective dis-
order and had been stabilized on an oral antipsychotic regimen
for at least 4 weeks. Exclusion criteria were current treatment with
clozapine, presence of DSM-IV-defined substance abuse or de-
pendence within the preceding 3 months, a neurological or med-
ical condition that could adversely influence patient safety or
evaluation, pregnancy, demonstrated lack of response to oral ris-
peridone in the past, or concomitant medications that could
compromise D2 evaluation (e.g., nonantipsychotic agents with
dopamine agonist or antagonist properties).
During a 2-week run-in phase, antipsychotics other than oral
risperidone were discontinued and replaced with oral risperi-
done at flexible doses ranging from 1 to 6 mg/day. Thus, all sub-
jects were receiving oral risperidone during this phase, and the
dose of long-acting risperidone that they received thereafter was
dependent on the oral risperidone dose at the end of the run-in
phase. Specifically, they were assigned to one of the three doses of
long-acting risperidone as follows: those receiving 1–2 mg/day or
3–4 mg/day of oral risperidone were assigned to the 25-mg and
50-mg doses of long-acting risperidone, respectively; subjects as-
signed to the 75-mg dose of long-acting risperidone were those
receiving 5–6 mg/day of oral risperidone. Supplementary oral ris-
peridone doses (1–6 mg/day) could be used for the first 2–3 weeks
following the switch, although this was not required in any of the
cases reported here.
Long-acting risperidone was administered every 2 weeks, and
at least five consecutive injections were administered before PET
was carried out. Participants were scanned twice during the 2-
week injection interval: within 3 days following injection (postin-
jection) and within 5 days before the next injection (preinjection).
D2 occupancy was established using [11C]raclopride following
the same procedure employed at our center and detailed previ-
ously (22). PET scanning was conducted using a GEMS PC2048-
Plus PET scanner (GE Medical Systems, Milwaukee) that pro-
duced 15 slices (thickness: 6.5 mm) with a resolution of about 5–6
mm in air. Patients were scanned lying down, with fixation of their
heads achieved by use of a thermoplastic face mask (Tru-Scan
Imaging, Annapolis, Md.).
Following injection of 10 mCi of high-specific-activity
[11C]raclopride (>300 Ci/mmol) using a bolus plus infusion pro-
tocol (23–26), a series of emission scans were obtained for 75 min-
utes. The regions of interest were the caudate/putamen, with the
cerebellum used as a reference region. The regions of interest
were drawn directly on averaged PET images and transferred to
the dynamic PET images to obtain a time activity curve. An aver-
age of the striatum/cerebellum ratio minus one obtained be-
tween 30 and 75 minutes of scanning was taken as a measure of
the equilibrium binding potential (27). Receptor occupancy was
then calculated as the percentage reduction of receptor binding
potential with drug treatment relative to baseline, using age-cor-
rected measures of binding potential from a previously collected
dataset of unmedicated comparison subjects obtained with a
similar methodology. This comparison group consisted of 22
healthy subjects and nine antipsychotic-naive patients with a di-
agnosis of schizophrenia or schizophreniform disorder (mean
age=31.5 years, SD=8.51, range=19–47). Since the mean binding
potential in the healthy subjects (mean=2.7, SD=0.4) did not dif-
fer significantly from that of the antipsychotic-naive subjects
(mean=2.9, SD=0.4) (t=0.98, df=29, p=0.30), the data from the two
groups were combined to obtain the regression equation for the
age-matched estimate of binding potential in the occupancy cal-
culation (binding potential=age ×0.03 + 3.8; R2=0.6).
FIGURE 1. Dopamine D2 Receptor Occupancy Levels at Two
Time Points Over the 2-Week Injection Interval for Nine Pa-
tients With Schizophrenia or Schizoaffective Disorder Re-
ceiving Long-Acting, Injectable Risperidone (25, 50, or 75
mg)a
a Hashed lines represent D2 occupancy thresholds associated with
clinical response and extrapyramidal symptoms from other reports
(17, 18).
b Within 3 days after the injection.
c Within 5 days of the next injection.
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FIGURE 2. Relationship Between D2 Receptor Occupancy
and Plasma Risperidone Plus 9-Hydroxyrisperidone Levels
in Nine Patients With Schizophrenia or Schizoaffective Dis-
order Receiving Long-Acting, Injectable Risperidone (25,
50, or 75 mg) Every 2 Weeksa
a The regression line was fit to the following rectangular hyperbolic
equation: occupancy=α × [plasma level/(plasma level plus ED50)],
where α is the maximal receptor occupancy, and ED50 is the plasma
risperidone plus 9-hydroxyrisperidone level resulting in 50% maxi-
mal receptor occupancy. Maximal occupancy α was constrained to
100% to reflect the expected maximal occupancy at higher plasma
levels. Each subject is represented by two points, representing the
two scans carried out over the course of an injection interval.
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Venous blood was drawn for drug and prolactin concentrations
at the time of the PET scans. For risperidone, blood samples were
collected in heparinized tubes and centrifuged for 10 minutes at
2500 rpm within 2 hours of collection. Separated plasma was
stored at –20°C for transport, and concentrations of risperidone
plus 9-hydroxyrisperidone were determined by means of a vali-
dated radioimmunoassay method (11). Prolactin levels were de-
termined by using a two-site chemiluminometric immunoassay
with a minimal detectable limit of 0.3 ng/ml and a coefficient of
variance of 3.6%–4.5% (ACS, CIBA-Corning Diagnostics, East Wal-
pole, Mass.).
Statistical analyses were carried out using SPSS (SPSS Inc., Chi-
cago). Bivariate correlation analysis was used to examine the rela-
tionship between the primary variables of interest. Nonlinear re-
gression analysis was used in the estimation of plasma
risperidone plus 9-hydroxyrisperidone level associated with 50%
D2 receptor occupancy.
Results
Nine participants (seven men and two women) com-
pleted the study. The group’s mean age was 34 years (SD=
9, range=21–46), and the dosage breakdown was as fol-
lows: 25 mg (N=2), 50 mg (N=5), and 75 mg (N=2).
As seen in Figure 1, D2 occupancy levels, measured at
the two time points (postinjection and preinjection) over
the 2-week injection interval, increased in a dose-depen-
dent fashion (25 mg: mean=71.0% [SD=5.7] and 54.0%
[SD=1.4], respectively; 50 mg: mean=74.4% [SD=10.4] and
65.4% [SD=2.1]; 75 mg: mean=81.5% [SD=5.0] and 75.0%
[SD=5.7]). Conversely, a comparison across all doses over
the two time points indicated a significant reduction in
both D2 occupancy (t=3.67, df=8, p=0.006) and plasma
concentrations of risperidone plus 9-hydroxyrisperidone
(t=3.35, df=8, p=0.01). Eight of nine participants showed
an expected decline in both of these measures over the
course of the injection interval (Table 1). One participant
showed a small increase in occupancy that paralleled a
modest increase in plasma levels (patient 4), but given the
test-retest standard deviation of 6% in our lab this change
is not significant.
Dose showed a significant correlation with plasma ris-
peridone plus 9-hydroxyrisperidone concentrations (r=
0.63, df=7, p=0.006), even after we controlled for time (r=
0.69, p=0.002). The relationship between plasma concen-
tration and D2 occupancy was captured by a saturating hy-
perbola (Bmax constrained to 100%), with the estimated
plasma concentration associated with 50% D2 occupancy
(ED50) being 11.06 ng/ml (95% confidence interval=9.15–
12.96) (Figure 2).
Mean prolactin values at the two time points (postinjec-
tion and preinjection) over the 2-week injection interval
were 57.11 µg/liter (SD=44.97) and 44.59 µg/liter (SD=
38.30), respectively, representing a nonsignificant differ-
ence (t=0.74, df=23, p=0.47). There was no significant cor-
relation between prolactin concentrations and plasma
concentrations of risperidone plus 9-hydroxyrisperidone
(r=0.32, p=0.12) or D2 receptor occupancy (r=0.34, p=0.10).
We sampled only a small subgroup of the larger clinical
sample, and the specific findings of the latter have been
reported elsewhere (13). All subjects participating in the
PET study either remained stable or showed clinical im-
provement during the trial, with the exception of one indi-
vidual (patient 8) who showed a 1-point Clinical Global
Impression deterioration. Extrapyramidal symptom
scores, as measured by the Extrapyramidal Symptom Rat-
ing Scale, remained low in all dose groups throughout the
PET study.
Discussion
With any new medication, it is critical that guidelines re-
garding optimal dosing be established. Previous PET data
have indicated that optimal clinical response occurs when
at least 65% of striatal D2 receptors are occupied, while the
risk of extrapyramidal symptoms increases notably at D2
occupancy levels above 80% (17, 18). The present findings
indicate that long-acting injectable risperidone, even at a
dose of 25 mg every 2 weeks, exceeds the threshold associ-
TABLE 1. Individual D2 Occupancy, Risperidone Plus 9-Hydroxyrisperidone, and Prolactin Levels at Two Time Points Over
the 2-Week Injection Interval for Nine Patients With Schizophrenia or Schizoaffective Disorder Receiving Long-Acting,
Injectable Risperidone (25, 50, or 75 mg)
Patient Gender
Age 
(years) Dose (mg)
Time Point During 2-Week Injection Intervala
Postinjection Preinjection
D2 Receptor 
Occupancyb 
(%)
Risperidone Plus 
9-Hydroxyris-
peridone (ng/ml)
Prolactinc 
(µg/ml)
D2 Receptor 
Occupancyb 
(%)
Risperidone Plus 9-
Hydroxyris-
peridone (ng/ml)
Prolactinc 
(µg/ml)
1 M 23 25 75 41.5 32 53 8.2 20
2 F 35 25 67 25.2 141 55 10.4 90
3 M 45 50 85 22.8 18 64 19.8 19
4 M 21 50 59 15.5 26 63 18.1 21
5 M 46 50 72 40.9 11 65 36.2 12
6 M 34 50 83 62.6 35 67 29.7 18
7 M 38 50 73 29.1 55 68 25.2 54
8 F 24 75 85 77.7 93 79 55.7 112
9 M 43 75 78 58.1 103 71 33.3 98
a Postinjection: within 3 days after the injection; preinjection: within 5 days of the next injection.
b Determined through a  [11C]raclopride PET scan.
c Normal values: male=3–13 µg/liter; female=3–27 µg/liter.
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ated with clinical response. As expected, D2 occupancy was
dose-dependent, with only the highest dose employed (75
mg) approximating the threshold that has been associated
with extrapyramidal symptoms in previous studies.
These findings suggest that for most patients treated
with long-acting risperidone, clinical efficacy should be ex-
pected at doses of 25–50 mg. This corroborates the existing
clinical evidence showing no additional clinical benefit at
higher doses (14). Moreover, our PET results suggest that
dosing at 75 mg every 2 weeks may be associated with
some degree of increased risk of extrapyramidal symp-
toms, supporting the observation of a dose-dependent risk
of extrapyramidal symptoms in the clinical setting (14).
Mean D2 occupancy levels toward the end of the injec-
tion interval for the 50- and 75-mg doses exceeded 65%,
while for the 25-mg dose the end-of-interval occupancy
level was 54%. At first glance, these data might be seen as
suggesting that individuals receiving 25 mg would be vul-
nerable to relapse toward the end of the injection interval.
However, maintenance of D2 occupancy levels above the
65% threshold may not be necessary for clinical response.
It has been shown, for example, that individuals can be
stabilized on a regimen of haloperidol decanoate adminis-
tered every 4 weeks, despite mean D2 occupancy levels de-
creasing from 73% (range=60%–82%) at week 1 to 53%
(range=20%–74%) at week 4 (21). Indeed, there is a grow-
ing body of evidence to suggest that there may be clinical
advantages to avoiding sustained, high D2 blockade (28).
Previous work from our center with oral risperidone,
which evaluated the relationship between D2 occupancy
and risperidone plus 9-hydroxyrisperidone, established
an ED50 of 6.08 ng/ml (95% CI=4.8–7.3) (29). In contrast,
the calculated ED50 here was 11.06 ng/ml (95% CI=9.15–
12.96). This discrepancy may reflect study group size: in
the first report the curve was established based on nine
data points, including one significant outlier, whereas the
current estimate was constructed from twice as many data
points. There are well-recognized concerns regarding the
impact of inter- and intraindividual variability in plasma
antipsychotic levels and efforts to establish “therapeutic
windows” (30–32). Bearing in mind this caveat, the current
estimate actually dovetails nicely with a more recent re-
view of this topic suggesting an optimal therapeutic range
for risperidone plus 9-hydroxyrisperidone of 20–60 ng/ml
(33). As seen in Figure 2, 20 ng/ml is associated with 65%
D2 occupancy, while 60 ng/ml represents 84% D2 occu-
pancy. Thus, the lower level meets the threshold associ-
ated with optimal clinical response, whereas the upper
limit is just over the threshold linked to increased extrapy-
ramidal symptom risk (18), which in turn may compro-
mise clinical outcome.
The lack of correlation between prolactin and D2 occu-
pancy was not entirely unexpected, since factors mediat-
ing prolactin secretion are complex (34). Our own exami-
nation of this issue has in the past provided mixed results
(17, 22), and efforts to establish a threshold for hyperpro-
lactinemia in the same fashion as clinical response and ex-
trapyramidal symptoms have not met with the same de-
gree of agreement (17, 35).
A comment is warranted regarding timing of the PET
scans in this study and the actual pharmacokinetics of
long-acting risperidone. The two points used here were
chosen to reflect the time frame of the recommended 2-
week injection interval, and in so doing provide a reflec-
tion of occupancy through the cycle of treatment at steady
state. This needs to be distinguished, however, from the
actual pharmacokinetics of single- and multiple-dose
long-acting risperidone (11). According to single-dose
data an injection’s peak occurs approximately 4–6 weeks
later, meaning that the main release phase is not observed
until after several injection intervals. Over the course of an
injection interval at steady state, concentrations of the ac-
tive moiety (Cmax to Cmin) decrease by approximately
50%–60%, and while this rate of decrease is notably greater
than what is observed in terms of changes in D2 occu-
pancy, we are reminded that a significant dissociation be-
tween brain and plasma kinetics in this regard has been
reported with antipsychotics (36).
At least several limitations qualify our conclusions. PET
studies of this sort involve limited numbers of patients,
much smaller than what would be required to definitively
analyze the relationship between dose/receptor occu-
pancy and response/side effects. As a result, to make clin-
ical inferences we must extrapolate the D2 occupancy data
to other larger clinical trials (13, 14). In addition, by focus-
ing on the D2 story we do not address the potential contri-
bution of other receptors and systems in a class of medica-
tions that are best characterized by their pharmacological
heterogeneity (37–39). Even confining our comments to
D2, the use of [11C]raclopride as the ligand focuses on stri-
atal D2 receptor occupancy. However, it can be argued that
D2 receptor occupancy in other areas is involved in clinical
response and that, further, there is evidence that atypical
agents may show differential D2 occupancy between stri-
atal and extrastriatal regions (40–47). However, having
raised each of these concerns, we are somewhat reassured
by the fact that the present data are in line with existing
clinical trial and plasma drug data (13, 14, 33) as well as re-
cently published PET data from another center (48).
In this particular study, patients were first switched to
oral risperidone and then to the depot risperidone formu-
lation on the basis of the final oral dose. Establishing com-
parable doses between the two formulations is compli-
cated by the more complex pharmacokinetics of long-
acting risperidone and differences in bioavailability. How-
ever, the PET data now available lend support to the posi-
tion that long-acting risperidone doses of 25–75 mg are in
line with oral risperidone doses of 2–6 mg (48).
In summary, the PET findings reported here support
available clinical evidence indicating that dosing long-act-
ing risperidone at 25–50 mg every 2 weeks is sufficient in at-
taining clinical response with minimal risk of extrapyrami-
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dal symptoms. In addition, they provide further data
regarding the relationship between plasma drug levels and
D2 occupancy. Having this information may assist clinicians
as they familiarize themselves with long-acting injectable
risperidone and incorporate it into their clinical practice.
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